
Market Rumors—nripn—February 8, 2026
Abivax Eli Lilly Acquisition speculation has dominated biotech headlines through Q1 2026. The French biotech's CEO Marc de Garidel dismissed the chatter as "noise" on January 20. By that point, shares had surged more than 2,000% between July and December on positive Obefazimod trial data. By contrast, French newsletter La Lettre reported that Eli Lilly









